CDK8-IN-6

CDK8-IN-6 (compound 9) is a potent cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 13 nM. CDK8-IN-6 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 11.2, 7.5, 8.6, 20.5, 12.5-25 µM, respectively. CDK8-IN-6 has the potential for the research of AML-cancer[1].

Product Specifications

CAS Number

[2415156-27-1]

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cdk8-in-6.html

Solubility

10 mM in DMSO

Smiles

C[C@@]12C(C3=CC(Cl)=CN=C3)=CC[C@@]1([H])[C@]4([H])CC[C@@]5([H])C[C@H](N(C)C)CC[C@]5(C)[C@@]4([H])CC2

Molecular Formula

C26H37ClN2

Molecular Weight

413.04

References & Citations

[1]Solum E, et al. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation. Bioorg Med Chem. 2020 May 15;28 (10) :115461.